Pfizer
Pfizer's stock has been falling for nearly two and a half years due to declining demand for its COVID-19 vaccine and Paxlovid antiviral drug. However, analysts remain bullish about Pfizer's long-term prospects. The average analysts' 12-month price target reflects an upside potential of around 22%.
Pfizer's launches of new products should generate additional revenue to compensate for sales losses from patent expirations. Its acquisitions should also pay off with promising new products added to its lineup.
Pfizer's stock is undervalued, trading below 11.9 times forward earnings. It also offers a juicy dividend yield of nearly 6.6%.
Brookfield Infrastructure
Brookfield Infrastructure owns a diversified portfolio of infrastructure assets, including utilities, rail, toll roads, terminals, pipelines, data centers, and cell towers. Its strategy of acquiring top assets, improving them, and selling mature assets should enable the company to grow funds from operations (FFO) per unit by 10% or more annually.
Analysts are upbeat about Brookfield Infrastructure's stock. Seven of the nine analysts surveyed by LSEG in April rate the stock as a buy or strong buy. The consensus 12-month price target is roughly 39% higher than the current price.
Brookfield Infrastructure is committed to growing its distribution by 5% to 9% each year. Its distribution yield tops 5.9%.
Brookfield Renewable
Brookfield Renewable owns hydroelectric, wind, solar, and distributed energy facilities across the world. The company expects to invest at least $7 billion in new renewable energy assets over the next five years. It should benefit from tailwinds including aggressive carbon emissions